31 March 2008: Prof. Antonio Tiengo Appointed to CM&D Pharma Scientific Board Chertsey, 31st March, 2008. CM&D Pharma Limited, the European niche specialty company, today announced the appointment of Professor Antonio Tiengo to its Scientific Board. Prof. Tiengo is an expert in metabolic diseases, and in particular diabetes, and is a member of the American Diabetes Association, as well as the European Society for the Study of Diabetes.  He has served as a reviewer for several leading international journals focusing on diabetes and metabolic disease. Having qualified as a doctor at the University of Padova, Prof. Tiengo completed his post-doctoral fellowship in Diabetology at the University of Paris, before returning to Italy to teach.  He served as President of the Italian Society of Diabetology, and progressed to be Dean of the Faculty of Medicine at the University of Padova. Stephen Appelbee, CEO of CM&D Pharma said: ‘Professor Tiengo brings a true clinical perspective to the evaluation of our research findings, valuing clinical benefit above anything else.  His expertise is particularly important in the light of our recent agreement with Natreon, Inc. to set up Puredel Limited, a company devoted to the development of Ossulin™, an oral presentation of insulin.’ Ends Notes to Editors About CM&D Pharma Limited CM&D Pharma Limited is a European niche specialty company founded in 2007. CM&D plans to become one of the few pan-European pharmaceutical companies targeting specialists in the five major European markets (France, Germany, Italy, Spain and the UK) with its own commercial organisation.  It is establishing its own niche product and technology platform for in-house development, and will operate through a unique model of concerted marketing and development. About Puredel Limited Puredel will focus its initial efforts on the development of Ossulin, which has shown promising results in preliminary animal and human studies.  Puredel will also explore other target molecules which are currently injected, and whose oral administration would greatly improve patient convenience and compliance.  Natreon’s R&D staff and facilities in the United States and India will be committed to the success of Puredel. Puredel will coordinate the product development of Ossulin up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America. Further information: Stephen Appelbee, CEO, +44 1932 796083, appelbee@cmdpharmaltd.com Ossulin™ is a trade mark of CM&D Pharma Limited > Back